Equities

Korro Bio Inc

KRRO:NAQ

Korro Bio Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)35.79
  • Today's Change-2.72 / -7.05%
  • Shares traded41.36k
  • 1 Year change+81.19%
  • Beta2.1832
Data delayed at least 15 minutes, as of Sep 20 2024 18:27 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments16683131
Total Receivables, Net--0.450.14
Total Inventory------
Prepaid expenses3.023.693.71
Other current assets, total3.560.260.19
Total current assets17387135
Property, plant & equipment, net433237
Goodwill, net------
Intangibles, net------
Long term investments--012
Note receivable - long term------
Other long term assets2.712.032.02
Total assets222121185
LIABILITIES
Accounts payable7.283.112.75
Accrued expenses127.397.73
Notes payable/short-term debt000
Current portion long-term debt/capital leases--10.000.83
Other current liabilities, total0.400.530.12
Total current liabilities192111
Total long term debt04.1714
Total debt01415
Deferred income tax------
Minority interest------
Other liabilities, total322729
Total liabilities525255
SHAREHOLDERS EQUITY
Common stock0.010.040.04
Additional paid-in capital353331311
Retained earnings (accumulated deficit)(183)(262)(180)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0(0.2)(0.06)
Total equity17069131
Total liabilities & shareholders' equity222121185
Total common shares outstanding8.020.710.69
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.